Intrathecal chemotherapy with methotrexate, a folate antagonist, is widely used to treat central nervous system malignancies. The mechanisms underlying methotrexate-induced neurotoxicity are unclear but may be related to increased homocysteine levels. Intrathecal methotrexate-induced myelopathy mimicking subacute combined degeneration, with normal B12 levels, has been documented. We examined treatment and magnetic resonance imaging (MRI) characteristics of 13 patients with leukemia who received intrathecal methotrexate and developed urinary and bowel incontinence, ascending motor weakness, and sensory loss with dorsal column hyperintensity on MRI between 2000 and 2016. Cerebrospinal fluid evaluation was negative for leukemia in all patients and positive for elevated protein in 12 patients. Seven of eight patients with available data had reduced serum folate, increased serum homocysteine, or both, implicating methotrexate as the cause of neurotoxicity. Autopsy of one patient revealed loss of myelinated axons in the posterior columns. These findings suggest that methotrexate neurotoxicity may be mediated by folate antagonism. Awareness and a high index of suspicion of these characteristic clinical and radiographic features in patients who develop myelopathy after intrathecal methotrexate may help to avoid additional neurotoxic therapy in such patients. 
| I N T R O D U C T I O N
The combination of systemic chemotherapy and aggressive prophylaxis for central nervous system (CNS) disease represents the cornerstone of therapy for acute leukemias. 1 The antimetabolite, folate antagonist methotrexate is a central component of treatment; however, a wellknown risk of intrathecal or intravenous methotrexate is acute, subacute, and late neurotoxicity. 2 The most commonly reported type of methotrexate-induced neurotoxicity is leukoencephalopathy, which can be acute or late and transient or permanent and is visualized on T2-weighted magnetic resonance imaging (MRI) as abnormal hyperintensities in the deep white matter of the brain. 3, 4 Reports of myelopathy after methotrexate therapy, however, have been rare. We previously published a series based on seven leukemia patients who developed intrathecal chemotherapy induced myelopathy at our institution between 2010 and 2014. 5 Several case reports have documented myelopathy in patients with leukemia characterized on MRI by T2 signal abnormalities in the dorsal horns; potential etiologies include tion sense and progresses to lower extremity anesthesias and paraplegia. 16 The similarities in the clinical and radiographic presentation between methotrexate myelopathy and subacute combined degeneration suggest a shared pathophysiology. To investigate this possibility, we identified 13 patients with irreversible myelopathy after receipt of CNS-directed therapy for leukemia who were found to have MRI T2
abnormalities in the dorsal columns. We evaluated clinical and radiographic findings in those patients.
| MATERIALS A ND METHODS
With the approval of our institutional review board, we used a tool for fast analytic search of all electronic MRI reports of patients presenting 
| R E S U LTS
Patient and treatment characteristics for the eight male and five female patients that developed dorsal column myelopathy are listed in Table   1 . Two patients had received primary treatment at outside institutions and presented to MD Anderson with myelopathy. All patients had received intrathecal methotrexate for the treatment of leukemia, either as single-agent therapy or in combination with cytarabine and a steroid (46%). The median number of intrathecal treatments was 17 (range 3-36).
T2 dorsal cord hyperintensity ( Figure 1 ) was noted in all patients.
Initial MRI scans obtained when symptoms arose had been reported as normal in seven patients (54%); re-review of these scans when subsequent scans showed abnormalities revealed that subtle T2 changes had been present in four of those cases. Axial T2 images are not obtained routinely at our institution; rather, only sagittal T2 images are acquired.
In several patients whose initial MRI studies had been considered "nor- 18, 19 were significantly elevated in all four patients assessed for this marker.
Serum folate levels were measured in eight patients (62%) when symptoms arose and were below normal in six patients and normal in two. Serum vitamin B12 levels, measured in 10 patients, were normal in 9. Elevated levels of homocysteine, an amino acid that requires folic acid for conversion to methionine, 20 have been implicated in vascular disease 21 and in methotrexate neurotoxicity. 20, 22, 23 Deficiencies in vitamin B12 or folic acid can lead to increased homocysteine levels, whereas vitamin B12 deficiency alone leads to elevation of serum methylmalonic acid. 24 Serum homocysteine levels were measured in four patients before vitamin B12 and folate repletion, and were elevated in all four; levels of methylmalonic acid, however, were normal, suggesting a deficiency in folate, but not in vitamin B12, in these patients.
Although we attempted repletion with B12 and folate in this patient population, unfortunately it did not result in neurologic improvement. Another approach for reducing symptoms of methotrexate-induced CNS toxicity is the administration of dextromethorphan, a non-competitive antagonist of N-methyl-D-aspartate receptors that are excessively activated by homocysteine and other excitotoxic amino acids. 25 Two of the patients in our series received dextromethorphan, but without significant durable improvement.
Eleven patients in our study (85%) had additional CNS treatment after the initial appearance of myelopathy because of concern for leukemia infiltration; two of these patients had received radiation therapy, one to the craniospinal axis and the other to T10 through the sacrum.
Postmortem examination of the latter patient revealed degeneration in the dorsal columns in the un-irradiated cervical spinal cord, most prominently within the fasciculus gracilis, an ascending tract carrying sensory fibers from the lower thoracic, lumbar, and sacral levels to the brain 
| DISCUSSION
Patients with hematologic malignancies, especially leukemia, are at increased risk of neurologic toxicity due to sequelae of central nervous system (CNS) directed therapy, direct cancer effects or from immune 20 In a study of 23 pediatric cancer patients that received methotrexate and 34 control patients who did not, significantly higher levels of CSF homocysteine were present among the methotrexate treated children.
Furthermore, patients with neurotoxicity at the time of CSF collection had the highest homocysteine levels. Similar findings of elevated homocysteine correlating with neurotoxicity after methotrexate have been reported based on serum homocysteine levels. 22 Among 53 pediatric patients with acute lymphoblastic leukemia (ALL) that received high dose methotrexate, the serum homocysteine levels were higher after methotrexate administration than before. Furthermore, patients that experienced seizures tended to have higher plasma homocysteine levels. Although serum homocysteine data was only available for four patients in our series, it was significantly elevated in all four patients. Interestingly, in a case report of a 41-year-old male with T-cell ALL that received both systemic and intrathecal methotrexate and developed irreversible myelopathy characterized by T2 hyperintensity in the dorsal columns on MRI, the authors attributed his myelopathy to nelarabine. 13 His folate and vitamin B12 levels were reported as normal. In this case report, the serum homocysteine levels were abnormally high at 198 mg/dL (normal 14-58 mg/dL). We propose that this patient had myelopathy induced by methotrexate and not nelarabine, given the history of methotrexate therapy and elevated homocysteine levels, despite the normal folic acid levels. Indeed, states of folate deficiency have been reported with normal serum level of folic acid. 28 Other reports of dorsal column myelopathy attributed to nelarabine have been published. 14, 29 In each of these reports intrathecal and/or systemic methotrexate were also given. This raises the question of whether nelarabine is actually the causal agent in these cases. In our series only two patients had ever received nelarabine therapy.
Because low pretreatment serum folate levels (less than 10 nmol/ L) have been shown to increase homocysteine levels, screening patients for low folate levels before methotrexate administration could be considered, although this practice must be weighed against the risk of "folate over-rescue," which is thought to reduce the anti-neoplastic effectiveness of methotrexate. 30, 31 Unfortunately, the administration of B12 and folate did not result in neurologic improvement in our There are limitations to our study and several questions remain unanswered. Serum folate and homocysteine levels were available only for a fraction of the patients in this series, therefore it is unknown if the other patients had the same serum findings. Furthermore CSF homocysteine levels were not obtained in any patient. It is unclear if elevation of homocysteine in the spinal fluid may be of greater diagnostic value due to increased sensitivity. Also due to the heterogeneity in the chemotherapy drugs given to these 13 patients, it is plausible that another drug may be the causative agent. Other factors may have also contributed to the dorsal myelopathy in these patients, such as immune dysfunction as has been reported previously. 15 Given the potential for this radiographic finding to be overlooked by radiologists it is likely that there have been other cases of dorsal myelopathy that were not recognized.
In conclusion, we assert that treatment-related myelopathy should always be considered when patients with leukemia present with neurologic abnormalities. At our institution, standard procedure now includes obtaining both axial and sagittal T2 MR images from patients with leukemia in whom treatment-related toxicity is suspected. CSF levels of protein and myelin basic protein should be measured; if they are elevated, methotrexate-mediated toxicity may be causing the myelopathy.
Future studies of genetic causes of excessive methotrexate toxicity may help to identify patients at high risk of developing severe dorsal myelopathy.
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